In medical news:

The National Institute on Drug Abuse (NIDA) announced the FDA submission of a new form of nasal naloxone, the product of the institute’s partnership with Adapt Pharma. Naloxone rapidly reverses the effects of opioid overdose and can save lives when administered correctly. Currently, the only FDA-approved use of naloxone is as an intramuscular injection, though there is a concentrated nasal formulation used off-label. An on-label nasal formulation could increase access and broaden the range of people that are able to administer the medication, including chronic opioid users themselves.

Read the release from NIDA here. Read full coverage from MedPage Today here.

Leave a Comment

Your email address will not be published. Required fields are marked *